PWMAG
VRTX icon

Pinnacle Wealth Management Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinnacle Wealth Management Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$390K Buy
874
+94
+12% +$43.8K 0.03% 335
2025
Q4 		$354K Buy
780
+15
+2% +$6.46K 0.02% 353
2025
Q3 		$300K Buy
765
+8
+1% +$3.34K 0.02% 320
2025
Q2 		$337K Buy
757
+26
+4% +$12K 0.03% 278
2025
Q1 		$354K Buy
731
+45
+7% +$21K 0.03% 258
2024
Q4 		$276K Sell
686
-25
-4% -$11.6K 0.03% 293
2024
Q3 		$331K Buy
711
+3
+0.4% +$1.44K 0.03% 260
2024
Q2 		$332K Buy
708
+33
+5% +$14.3K 0.03% 254
2024
Q1 		$282K Buy
675
+25
+4% +$10.6K 0.03% 273
2023
Q4 		$264K Hold
650
– – 0.03% 272
2023
Q3 		$226K Sell
650
-10
-2% -$3.5K 0.03% 281
2023
Q2 		$232K Sell
660
-40
-6% -$13.5K 0.03% 288
2023
Q1 		$221K Buy
+700
New +$210K 0.03% 283

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pinnacle Wealth Management Advisory Group's VRTX Position: Q1 2026 in Review

Pinnacle Wealth Management Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, buying an estimated $43.8K and bringing the position to 874 shares worth $390K. The position accounts for 0.03% of the portfolio, ranked #335.

Pinnacle Wealth Management Advisory Group first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Pinnacle Wealth Management Advisory Group held 874 shares of Vertex Pharmaceuticals worth $390K as of Q1 2026.
  • Pinnacle Wealth Management Advisory Group bought 94 Vertex Pharmaceuticals shares in Q1 2026, an estimated $43.8K.
  • Vertex Pharmaceuticals made up 0.03% of Pinnacle Wealth Management Advisory Group's portfolio in Q1 2026, its #335 holding.
  • Pinnacle Wealth Management Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Pinnacle Wealth Management Advisory Group's 13F filing for Q1 2026, filed 21 Apr 2026.